CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.

EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a MoU to establish the mRNA production platform in Egypt.